Zofia Piotrowska

Zofia Piotrowska

UNVERIFIED PROFILE

Are you Zofia Piotrowska?   Register this Author

Register author
Zofia Piotrowska

Zofia Piotrowska

Publications by authors named "Zofia Piotrowska"

Are you Zofia Piotrowska?   Register this Author

41Publications

1351Reads

34Profile Views

Resistance to First-Line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue.

Clin Cancer Res 2020 Mar 26. Epub 2020 Mar 26.

Department of Medicine, Massachusetts General Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-20-0097DOI Listing
March 2020

Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.

J Thorac Oncol 2019 Oct;14(10):e226-e228

Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.05.046DOI Listing
October 2019

Diffuse Lung Metastases in -Mutant Non-Small Cell Lung Cancer.

Cancers (Basel) 2019 Sep 13;11(9). Epub 2019 Sep 13.

Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11091360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769768PMC
September 2019

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.

Clin Cancer Res 2018 12 28;24(24):6548-6555. Epub 2018 Aug 28.

Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1541DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295229PMC
December 2018

Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma.

J Thorac Oncol 2018 10;13(10):e204-e206

HealthPartners and Department of Medicine, University of Minnesota, Minneapolis, Minnesota.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183063
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.05.017DOI Listing
October 2018

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.

Oncologist 2018 09 27;23(9):1054-1062. Epub 2018 Apr 27.

Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192617PMC
September 2018

ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?

J Clin Oncol 2018 08 4;36(22):2241-2243. Epub 2018 Jun 4.

Zofia Piotrowska and Justin F. Gainor, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.79.3059DOI Listing
August 2018

Unlocking the Mystery of Small-Cell Lung Cancer Transformations in EGFR Mutant Adenocarcinoma.

J Clin Oncol 2017 09 10;35(26):2987-2988. Epub 2017 Jul 10.

Anna F. Farago, Zofia Piotrowska, and Lecia V. Sequist, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.5696DOI Listing
September 2017

The Role of Liquid Biopsies in Lung Cancer Screening.

Semin Roentgenol 2017 Jul 3;52(3):185-187. Epub 2017 Jun 3.

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.ro.2017.06.001DOI Listing
July 2017

Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer.

J Thorac Oncol 2017 03;12(3):419-421

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.01.018DOI Listing
March 2017

End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.

J Palliat Med 2016 12 14;19(12):1316-1319. Epub 2016 Sep 14.

2 Massachusetts General Hospital Cancer Center , Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jpm.2016.0180DOI Listing
December 2016

Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer.

J Thorac Oncol 2016 08 12;11(8):e95-e97. Epub 2016 Apr 12.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.03.020DOI Listing
August 2016

Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review.

JAMA Oncol 2016 Jul;2(7):948-54

Harvard Medical School, Boston, Massachusetts2Massachusetts General Hospital Cancer Center, Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.0333DOI Listing
July 2016

Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.

Cancer J 2015 Sep-Oct;21(5):371-7

From the Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000147DOI Listing
June 2016

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

JAMA Oncol 2016 Apr;2(4):541-3

Massachusetts General Hospital Cancer Center, Boston2Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.5009DOI Listing
April 2016

Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy.

J Thorac Oncol 2015 Nov;10(11):1601-7

*Department of Radiation Oncology, †Department of Radiology, and ‡Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000648DOI Listing
November 2015

Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?

Oncologist 2015 Nov 23;20(11):1230-2. Epub 2015 Oct 23.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0370DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718438PMC
November 2015

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.

Clin Cancer Res 2015 Sep 11;21(17):3924-33. Epub 2015 May 11.

Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587765PMC
September 2015

Rociletinib in EGFR-mutated non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1700-9

From Massachusetts General Hospital (L.V.S., R.S.H., J.L., Z.P.), Harvard Medical School (L.V.S., G.R.O., R.S.H., Z.P.), and Dana-Farber Cancer Institute (G.R.O.) - all in Boston; the Drug Development Department, Université Paris-Sud, Gustave Roussy Cancer Campus (J.-C.S.), and Institut Gustave Roussy (A.V.), Villejuif - both in France; the David Geffen School of Medicine, University of California, Los Angeles, Los Angeles (J.W.G., E.B.G., M.A.M., S.N.), and Stanford Cancer Institute, Stanford University, Stanford (H.A.W., J.W.N.) - both in California; the Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit (S.M.G., C.G., A.J.W.); University of Texas M.D. Anderson Cancer Center, Houston (V.P.); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); the Medical University of Gdansk, Gdansk, Poland (R.D.); the University of Colorado (D.L.A., D.R.C.) and University of Colorado Cancer Center (R.C.D.) - both in Aurora; and Clovis Oncology, San Francisco (M.R., C.A.K., S.J.-T., S.L.M., A.R.A.), Boulder, CO (J.I., D.D.), and Cambridge, United Kingdom (L.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1413654DOI Listing
April 2015